Online inquiry

IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12199MR)

This product GTTS-WQ12199MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CSF2 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000758.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1437
UniProt ID P04141
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ12199MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3274MR IVTScrip™ mRNA-Anti-TNF, ART621(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ART621
GTTS-WQ9584MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA JNJ-61186372
GTTS-WQ4475MR IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-931699
GTTS-WQ12863MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OPN-305
GTTS-WQ11997MR IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MM-121
GTTS-WQ5948MR IVTScrip™ mRNA-Anti-IGHE, CL-2C(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CL-2C
GTTS-WQ13655MR IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA RB4v1.2
GTTS-WQ2240MR IVTScrip™ mRNA-Anti-VWF, aVWF81(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA aVWF81
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW